Atrys Health, S.A. (ATRY.MC)

EUR 2.88

(1.77%)

Total Liabilities Summary of Atrys Health, S.A.

Atrys Health, S.A.'s latest annual total liabilities in 2023 was 332.45 Million EUR , down -9.59% from previous year.
Atrys Health, S.A.'s latest quarterly total liabilities in 2024 Q1 was 331.96 Million EUR , down -0.15% from previous quarter.
Atrys Health, S.A. reported annual total liabilities of 367.7 Million EUR in 2022, up 26.08% from previous year.
Atrys Health, S.A. reported annual total liabilities of 291.65 Million EUR in 2021, up 190.35% from previous year.
Atrys Health, S.A. reported quarterly total liabilities of 331.96 Million EUR for 2024 Q1, down -0.15% from previous quarter.
Atrys Health, S.A. reported quarterly total liabilities of 339.11 Million EUR for 2023 Q3, down -10.19% from previous quarter.

Annual Total Liabilities Chart of Atrys Health, S.A. (2023 - 2012)

Historical Annual Total Liabilities of Atrys Health, S.A. (2023 - 2012)

Year	Total Liabilities	Total Liabilities Growth
2023	332.45 Million EUR	-9.59%
2022	367.7 Million EUR	26.08%
2021	291.65 Million EUR	190.35%
2020	100.44 Million EUR	108.88%
2019	48.08 Million EUR	76.47%
2018	27.25 Million EUR	61.25%
2017	16.89 Million EUR	3.64%
2016	16.3 Million EUR	13.27%
2015	14.39 Million EUR	14.17%
2014	12.6 Million EUR	2.9%
2013	12.25 Million EUR	0.14%
2012	12.23 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	331.96 Million EUR	0.0%
2024 Q1	331.96 Million EUR	-0.15%
2023 Q3	339.11 Million EUR	-10.19%
2023 FY	332.45 Million EUR	-9.59%
2023 Q1	377.58 Million EUR	2.69%
2023 Q4	332.45 Million EUR	-1.96%
2023 Q2	377.58 Million EUR	0.0%
2022 Q1	352.99 Million EUR	21.03%
2022 FY	367.7 Million EUR	26.08%
2022 Q4	367.7 Million EUR	0.0%
2022 Q3	367.7 Million EUR	4.17%
2022 Q2	352.99 Million EUR	0.0%
2021 Q4	291.65 Million EUR	0.0%
2021 Q1	270.97 Million EUR	169.76%
2021 FY	291.65 Million EUR	190.35%
2021 Q2	270.97 Million EUR	0.0%
2021 Q3	291.65 Million EUR	7.63%
2020 Q2	51.5 Million EUR	0.0%
2020 Q4	100.44 Million EUR	-8.34%
2020 Q1	51.5 Million EUR	7.11%
2020 FY	100.44 Million EUR	108.88%
2020 Q3	109.59 Million EUR	112.76%
2019 FY	48.08 Million EUR	76.47%
2019 Q2	33.29 Million EUR	0.0%
2019 Q4	48.08 Million EUR	0.0%
2019 Q3	48.08 Million EUR	44.44%
2019 Q1	33.29 Million EUR	22.17%
2018 Q4	27.25 Million EUR	0.0%
2018 FY	27.25 Million EUR	61.25%
2018 Q2	14.07 Million EUR	0.0%
2018 Q1	14.07 Million EUR	-16.74%
2018 Q3	27.25 Million EUR	93.66%
2017 FY	16.89 Million EUR	3.64%
2017 Q4	16.89 Million EUR	-21.89%
2017 Q3	21.63 Million EUR	33.99%
2017 Q2	16.14 Million EUR	0.0%
2017 Q1	16.14 Million EUR	-0.98%
2016 Q2	15.5 Million EUR	0.0%
2016 Q1	15.5 Million EUR	0.0%
2016 FY	16.3 Million EUR	13.27%
2016 Q4	16.3 Million EUR	0.0%
2016 Q3	16.3 Million EUR	5.19%
2015 FY	14.39 Million EUR	14.17%
2014 FY	12.6 Million EUR	2.9%
2013 FY	12.25 Million EUR	0.14%
2012 FY	12.23 Million EUR	0.0%

Peer Total Liabilities Comparison of Atrys Health, S.A.

Name	Total Liabilities	Total Liabilities Difference
Biotechnologies Assets SA	10.07 Million EUR	-3199.681%
Oryzon Genomics S.A.	25.12 Million EUR	-1223.186%
Pharma Mar, S.A.	147.78 Million EUR	-124.96%
Laboratorios Farmaceuticos Rovi, S.A.	256.39 Million EUR	-29.668%